GO:0060334 regulation of type II interferon-mediated signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0060334 describes any process that modulates the rate, frequency, or extent of interferon-gamma (type II interferon)-mediated signaling.
• Type II interferon signaling is central to antiviral defense, immune surveillance, and inflammatory responses, and its dysregulation is linked to autoinflammation, cancer, and chronic infections [1,6,7].
• Key regulators include STAT1, IRF1, NLRC5, and PDL1, which fine-tune MHC class I induction and cytotoxic responses [5,7].
• Viruses such as SARS-CoV-2 and murine norovirus evade type II interferon responses by targeting STAT1-IRF1-NLRC5 or ISG15 effectors [7,8].
• CRISPR knockout, point mutation, knock-in, and overexpression models are essential to dissect causal roles of regulators in this pathway [5,7].
• EDITGENE provides end-to-end CRISPR services, including library screening and bioinformatics, to accelerate discovery in type II interferon regulation.
Description
The type II interferon-mediated signaling pathway is a critical arm of the immune response, primarily driven by interferon-gamma (IFN-γ), which coordinates antimicrobial and antitumor immunity. The Gene Ontology term GO:0060334, regulation of type II interferon-mediated signaling pathway, encompasses any process that modulates the rate, frequency, or extent of this signaling cascade. Understanding this regulation is vital because precise control of IFN-γ signaling ensures effective pathogen clearance while preventing immunopathology [1,6]. Dysregulated type II interferon signaling has been implicated in autoimmune diseases, chronic infections, and cancer immune evasion [1,5,6]. For researchers, GO:0060334 provides a framework to study how positive and negative regulators shape IFN-γ responses, from receptor engagement to transcriptional outputs. Recent studies have identified key modulators such as STAT1, IRF1, NLRC5, and PDL1 that directly influence the pathway's outcome [5,7]. Moreover, viral pathogens like SARS-CoV-2 and murine norovirus have evolved strategies to subvert these regulatory mechanisms, highlighting their therapeutic relevance [7,8]. This article synthesizes authoritative QuickGO data and verified PubMed literature to deliver a research-grade overview of GO:0060334, its molecular players, disease connections, and experimental approaches for investigation.
regulation of type II interferon-mediated signaling pathway At A Glance
| GO ID | GO:0060334 |
|---|---|
| GO term | regulation of type II interferon-mediated signaling pathway |
| Ontology | biological_process |
| Synonym | regulation of gamma-interferon-mediated signaling pathway; regulation of immune interferon signaling pathway; regulation of interferon-gamma-mediated signaling pathway; regulation of interferon-gamma-mediated signalling pathway; regulation of type II IFN-mediated signaling pathway |
| Major function | Modulates the rate, frequency, or extent of interferon-gamma-mediated signaling |
| Related pathway | JAK-STAT signaling, MHC class I antigen presentation, antiviral defense |
| Key regulators | STAT1, IRF1, NLRC5, PDL1, ISG15 |
| Disease relevance | Autoinflammation, cancer, viral infections, chronic graft-versus-host disease |
What Is GO:0060334?
GO:0060334, regulation of type II interferon-mediated signaling pathway, is defined as any process that modulates the rate, frequency, or extent of an interferon-gamma-mediated signaling pathway. In other words, it covers all molecular events that tune the strength, duration, or outcome of cellular responses to IFN-γ, the sole type II interferon. This regulation can occur at multiple levels, including receptor availability, JAK-STAT activation, transcription of interferon-stimulated genes, and feedback inhibition.
Why Is regulation of type II interferon-mediated signaling pathway Important in Cell Biology?
Regulation of type II interferon-mediated signaling is essential for balancing protective immunity and tissue damage. IFN-γ signaling is required for host defense against intracellular pathogens and for tumor immunosurveillance, but excessive or prolonged activation can drive autoinflammatory and autoimmune pathologies [1,6]. Understanding GO:0060334 helps identify therapeutic targets to boost immunity against infections and cancer or to dampen harmful inflammation [5,7].
• Controls antiviral and antibacterial immunity through IFN-γ-mediated gene expression.
• Regulates MHC class I antigen presentation, critical for CD8+ T cell responses.
• Dysregulation is linked to autoinflammatory diseases such as DNase II deficiency.
• Modulates cancer immune evasion via PDL1 and interferon signaling crosstalk.
• Influences chronic graft-versus-host disease through type I interferon processes.
• Viral pathogens target this pathway to escape immune clearance [7,8].
• Provides targets for immunotherapy and vaccine adjuvants [5,7].
• Essential for understanding interferon-mediated programmed cell death in colorectal cancer.
• Key to developing CRISPR-based models for gene function studies.
• Guides bioinformatics analysis of interferon-stimulated gene networks.
What Happens During regulation of type II interferon-mediated signaling pathway?
IFN-γ Receptor Engagement and JAK-STAT Activation
In simple terms: When IFN-γ binds to its receptor, it switches on a signaling cascade inside the cell.
IFN-γ binds to the IFN-γ receptor, leading to activation of JAK kinases and phosphorylation of STAT1. This step is a primary point of regulation, as the availability of receptor subunits and JAKs determines signal strength. Regulatory processes at this stage include modulation of receptor expression and activity of phosphatases that dephosphorylate STAT1.
STAT1 Nuclear Translocation and Transcriptional Complex Formation
In simple terms: Activated STAT1 moves into the nucleus to turn on specific genes.
Phosphorylated STAT1 forms dimers that translocate to the nucleus and bind to gamma-activated sequences (GAS) in target gene promoters. This step is regulated by nuclear import/export machinery and by cofactors such as IRF1, which cooperate with STAT1 to induce genes like NLRC5 and MHC class I. Negative regulators, including SOCS proteins, can attenuate this process.
Induction of Interferon-Stimulated Genes and MHC Class I Pathway
In simple terms: The signal turns on genes that help the cell fight infections and present antigens.
STAT1-IRF1-NLRC5 axis drives expression of MHC class I genes and other interferon-stimulated genes (ISGs). This axis is a key regulatory node; its inhibition by viral proteins or PDL1 signaling can blunt antigen presentation and cytotoxic T cell responses [5,7]. ISG15, an interferon-mediated effector, also modulates antiviral responses early in infection.
Feedback Inhibition and Signal Termination
In simple terms: The cell has brakes to stop the interferon response once the threat is controlled.
Regulation includes negative feedback loops involving SOCS1, SOCS3, and phosphatases that dephosphorylate JAKs and STAT1. PDL1 can also signal through conserved motifs to overcome interferon-mediated cytotoxicity, representing an extrinsic regulatory mechanism. Proper termination prevents chronic inflammation and autoimmunity.
Crosstalk with Other Interferon Pathways
In simple terms: Type II interferon signaling talks to type I and type III interferon pathways.
Type I (IFN-α/β) and type III (IFN-λ) interferons share components with the type II pathway, leading to crosstalk. For example, IL-1β amplifies IFN-α-induced antiviral responses, and type III interferon signaling is critical for controlling yellow fever virus [2,3]. This integration fine-tunes the overall antiviral state and is subject to regulation at multiple levels [2,3].
Key Genes Involved in GO:0060334 regulation of type II interferon-mediated signaling pathway
The following genes and proteins are central to the regulation of type II interferon-mediated signaling, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| STAT1 | Transcription factor mediating IFN-γ signaling; forms dimers to activate ISGs | Central node; knockout abolishes IFN-γ responses |
| IRF1 | Cooperates with STAT1 to induce MHC class I and other genes | Key regulator of antigen presentation |
| NLRC5 | Transcriptional activator of MHC class I genes downstream of IFN-γ | Target for viral evasion; knockout reduces MHC class I |
| PDL1 (CD274) | Signals through conserved motifs to overcome interferon-mediated cytotoxicity | Immune checkpoint; overexpression model for resistance |
| ISG15 | Interferon-mediated antiviral effector; ubiquitin-like modifier | Early antiviral defense; knockout increases susceptibility |
| JAK1 | Janus kinase phosphorylating STAT1 upon IFN-γ receptor engagement | Kinase essential for signal initiation |
| JAK2 | Janus kinase partnering with JAK1 in IFN-γ signaling | Kinase essential for signal initiation |
| IFNGR1 | Ligand-binding subunit of IFN-γ receptor | Determines sensitivity to IFN-γ |
| IFNGR2 | Signal-transducing subunit of IFN-γ receptor | Modulates receptor assembly and signaling |
| SOCS1 | Negative feedback regulator of JAK-STAT signaling | Knockout leads to hyperactivation |
| SOCS3 | Negative regulator of cytokine signaling | Modulates IFN-γ responses |
| IL1B | Amplifies IFN-α-induced antiviral responses | Crosstalk between inflammation and interferon |
| DNASE2 | Deficiency causes type I interferon-mediated autoinflammation | Model for autoinflammatory diseases |
| T-bet (TBX21) | Transcription factor in cytotoxic effectors; linked to type I interferon processes | Marker in chronic GVHD |
| NLRC5 | MHC class I transactivator; targeted by SARS-CoV-2 | Viral evasion mechanism |
| STAT1 | Also targeted by SARS-CoV-2 to inhibit MHC class I induction | Viral immune evasion |
| IRF1 | Targeted by SARS-CoV-2 to inhibit MHC class I induction | Viral immune evasion |
| ISG15 | Antiviral effector early in murine norovirus life cycle | Model for norovirus restriction |
How Is regulation of type II interferon-mediated signaling pathway Regulated?
Regulation of type II interferon-mediated signaling is achieved through multiple mechanisms. Positive regulators include JAK kinases, STAT1, and IRF1, which propagate the signal. Negative regulators include SOCS proteins, phosphatases, and PDL1, which attenuate or terminate signaling to prevent excessive inflammation [5,7]. Additionally, crosstalk with type I and type III interferon pathways, as well as inflammatory cytokines like IL-1β, can modulate the overall response [2,3]. Viral proteins often target key nodes such as STAT1-IRF1-NLRC5 to evade immune detection.
regulation of type II interferon-mediated signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| DNASE2 | Type I interferon-mediated autoinflammation | Knockout mouse or cell line |
| PDL1 (CD274) | Cancer immune evasion | Overexpression in tumor cells |
| STAT1 | Viral evasion (SARS-CoV-2) | Knockout or point mutation |
| ISG15 | Antiviral defense (norovirus) | Knockout mice or cells |
| IL1B | Amplification of antiviral responses | Overexpression or knockout |
Autoinflammatory Diseases
Deficiency in DNase II leads to type I interferon-mediated autoinflammation, highlighting how dysregulated interferon signaling can cause chronic inflammation. Although this primarily involves type I interferon, the regulatory principles overlap with type II interferon pathways, and understanding GO:0060334 can inform therapeutic strategies for autoinflammatory conditions.
Cancer Immune Evasion
PDL1 signals through conserved sequence motifs to overcome interferon-mediated cytotoxicity, allowing tumors to escape immune attack. Interferon-mediated programmed cell death in colorectal cancer is regulated by gut microbiota, linking type II interferon regulation to cancer biology. Targeting regulators of GO:0060334 may enhance immunotherapy efficacy [5,6].
Viral Infections
SARS-CoV-2 inhibits induction of the MHC class I pathway by targeting the STAT1-IRF1-NLRC5 axis, a key component of type II interferon signaling. ISG15 functions as an interferon-mediated antiviral effector early in murine norovirus infection, demonstrating the importance of this pathway in controlling viral replication. Type III interferon signaling is also critical for controlling yellow fever virus, showing crosstalk between interferon types.
Chronic Graft-versus-Host Disease
Increased T-bet+ cytotoxic effectors and type I interferon-mediated processes are observed in chronic graft-versus-host disease of the oral mucosa, indicating that interferon signaling dysregulation contributes to this condition. While type I interferon is implicated, type II interferon regulation may also play a role in the inflammatory milieu.
From regulation of type II interferon-mediated signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does STAT1 regulate IFN-γ-induced MHC class I? | STAT1 knockout cell line |
| Does PDL1 overcome interferon cytotoxicity? | PDL1 overexpression |
| Is ISG15 required for early antiviral defense? | ISG15 knockout mice |
| Does IL-1β amplify IFN-α responses? | IL1B overexpression or knockout |
| Does DNase II deficiency cause autoinflammation? | DNASE2 knockout mouse |
| Does SARS-CoV-2 target NLRC5? | NLRC5 knockout or tagged knock-in |
How to Study the regulation of type II interferon-mediated signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify ISGs after knockout |
| Phosphoproteomics | Phosphorylation of STAT1 and JAKs | Assess pathway activation |
| Flow cytometry | MHC class I surface expression | Validate antigen presentation |
| Immunofluorescence | STAT1 nuclear translocation | Visualize signaling dynamics |
| CRISPR screen | Genes affecting IFN-γ sensitivity | Discover novel regulators |
| Western blot | Protein levels and phosphorylation | Confirm knockout efficiency |
| qPCR | mRNA levels of target genes | Quantify transcriptional responses |
Transcriptomic Profiling (RNA-seq)
RNA sequencing measures global changes in gene expression upon modulation of type II interferon signaling. It can identify interferon-stimulated genes and pathways affected by CRISPR knockouts of regulators like STAT1 or IRF1.
Proteomics and Phosphoproteomics
Mass spectrometry-based proteomics quantifies protein abundance and phosphorylation events in the JAK-STAT pathway. This is useful to assess activation status of STAT1 and downstream effectors after genetic perturbation.
Flow Cytometry and Imaging
Flow cytometry measures surface MHC class I expression and immune cell phenotypes, while imaging visualizes STAT1 nuclear translocation. These methods validate functional consequences of regulatory gene edits.
CRISPR Library Screening
Genome-wide CRISPR screens identify novel regulators of type II interferon signaling by selecting for resistance or sensitivity to IFN-γ-mediated cytotoxicity. Hits can be validated individually [5,7].
How CRISPR Can Be Used to Study GO:0060334 regulation of type II interferon-mediated signaling pathway
Knockout
CRISPR knockout of genes such as STAT1, IRF1, or NLRC5 abolishes or reduces type II interferon signaling, enabling researchers to study their essential roles in MHC class I induction and antiviral defense.
Point Mutation
Introducing point mutations in STAT1 or PDL1 can dissect specific phosphorylation or signaling motifs, revealing how individual residues regulate interferon-mediated cytotoxicity [5,7].
Knock-in
Knock-in of tagged versions of STAT1 or IRF1 allows tracking of protein localization and interactions in live cells, providing insights into dynamic regulation of the pathway.
Overexpression
Overexpression of PDL1 or IL-1β can model gain-of-function states that overcome or amplify interferon responses, useful for studying immune evasion and inflammation [3,5].
How EDITGENE Supports regulation of type II interferon-mediated signaling pathway Research
Researchers studying regulation of type II interferon-mediated signaling pathway-related genes often need to determine whether a candidate gene is causally involved in the pathway or merely correlated with its activity. EDITGENE provides the CRISPR tools and services to establish causality through precise genome editing.
Contact EDITGENE today to design your custom CRISPR model for regulation of type II interferon-mediated signaling pathway research.
Frequently Asked Questions About regulation of type II interferon-mediated signaling pathway
What is GO:0060334?
GO:0060334 is the Gene Ontology term for regulation of type II interferon-mediated signaling pathway, defined as any process that modulates the rate, frequency, or extent of interferon-gamma-mediated signaling.
What genes are involved in regulation of type II interferon-mediated signaling pathway?
Key genes include STAT1, IRF1, NLRC5, PDL1, ISG15, JAK1, JAK2, and SOCS1, among others [5,7,8].
How does type II interferon signaling work?
IFN-γ binds its receptor, activating JAK-STAT signaling, leading to STAT1 phosphorylation, nuclear translocation, and induction of interferon-stimulated genes such as MHC class I.
What diseases are associated with dysregulated type II interferon signaling?
Dysregulation is linked to autoinflammatory diseases, cancer immune evasion, viral infections, and chronic graft-versus-host disease [1,4,5,6,7].
How can CRISPR be used to study GO:0060334?
CRISPR knockout, point mutation, knock-in, and overexpression models allow researchers to test the causal role of specific genes in the pathway [5,7].
What is the role of STAT1 in type II interferon signaling?
STAT1 is the central transcription factor that mediates IFN-γ-induced gene expression; its knockout abolishes key responses.
How do viruses evade type II interferon signaling?
Viruses such as SARS-CoV-2 target the STAT1-IRF1-NLRC5 axis to inhibit MHC class I induction, while others use ISG15-related mechanisms [7,8].
What methods are used to study regulation of type II interferon signaling?
Common methods include RNA-seq, phosphoproteomics, flow cytometry, immunofluorescence, and CRISPR screens [5,7].
What is the difference between type I and type II interferon signaling?
Type I interferons (IFN-α/β) primarily signal through STAT1-STAT2-IRF9, while type II interferon (IFN-γ) signals through STAT1 homodimers; crosstalk exists between them [2,3,7].
How does PDL1 regulate interferon-mediated cytotoxicity?
PDL1 signals through conserved sequence motifs to overcome interferon-mediated cytotoxicity, contributing to immune evasion.
Conclusion
GO:0060334, regulation of type II interferon-mediated signaling pathway, is a critical biological process that fine-tunes immune responses to pathogens and tumors. Its dysregulation underlies various diseases, from autoinflammation to cancer. Advances in CRISPR technology and bioinformatics are enabling precise dissection of its regulatory networks. EDITGENE offers comprehensive services to support researchers in modeling and understanding this pathway, ultimately aiding the development of novel therapeutics.
References
- 1. Rodero MP et al.. 2017. Type I interferon-mediated autoinflammation due to DNase II deficiency.. Nat Commun 8(1):2176 PMID: 29259162
- 2. Douam F et al.. 2017. Type III Interferon-Mediated Signaling Is Critical for Controlling Live Attenuated Yellow Fever Virus Infection In Vivo.. mBio 8(4) PMID: 28811340
- 3. Robichon K et al.. 2020. Identification of Interleukin1β as an Amplifier of Interferon alpha-induced Antiviral Responses.. PLoS Pathog 16(10):e1008461 PMID: 33002089
- 4. Imanguli MM et al.. 2009. Increased T-bet+ cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa.. Blood 113(15):3620-30 PMID: 19168793
- 5. Gato-Cañas M et al.. 2017. PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity.. Cell Rep 20(8):1818-1829 PMID: 28834746
- 6. Yao Q et al.. 2025. Role and mechanism of gut microbiota in regulating interferon-mediated programmed cell death in colorectal cancer.. Front Immunol 16:1724908 PMID: 41601698
- 7. Yoo JS et al.. 2021. SARS-CoV-2 inhibits induction of the MHC class I pathway by targeting the STAT1-IRF1-NLRC5 axis.. Nat Commun 12(1):6602 PMID: 34782627
- 8. Rodriguez MR et al.. 2014. ISG15 functions as an interferon-mediated antiviral effector early in the murine norovirus life cycle.. J Virol 88(16):9277-86 PMID: 24899198
